The addition of GnRH antagonists in intrauterine insemination cycles with mild ovarian hyperstimulation does not increase live birth rates--a randomized, double-blinded, placebo-controlled trial

Astrid EP Cantineau, A E P Cantineau, Ben J Cohlen, B J Cohlen, H Klip, Helen Klip, M J Heineman, The Dutch IUI Study Group Collaborators, Dutch IUI Study Group Collaborators, Annemieke Hoek, Cornelis B. Lambalk, Celeste J. Hamilton, P. F. van Bommel, P. A. van Dop, P. F. M. van der Heijden, P. De Sutter, T. D'Hooghe, Petra A Manger, Willem Ombelet, J. G. Santema
Human Reproduction · 2011 · vol. 26(5) , pp. 1104–1111 · doi:10.1093/humrep/der033 · PMID:21339196 · W2110040778
article OA: bronze CC0 ⤵ 2 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This RCT found that adding a GnRH antagonist to mild ovarian hyperstimulation cycles with intrauterine insemination did not increase live birth rates compared to placebo.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: This multicenter, double-blinded RCT investigated the efficacy of GnRH antagonists in cycles with mild ovarian hyperstimulation (MOH) followed by IUI in subfertile women. METHODS: Couples diagnosed with unexplained, male factor subfertility or associated with the presence of minimal or mild endometriosis were randomized with a computer-generated list of numbers by a third party in a double-blinded setting to receive either a GnRH antagonists or a placebo in 12 institutional or academic hospitals. All women were treated with recombinant FSH in a low-dose step-up regimen starting on Day 2-4 of the cycle. A GnRH antagonist was added when one or more follicles of 14 mm diameter or more were visualized. When at least one follicle reached a size of ≥18 mm, ovulation was induced by hCG injection. A single IUI was performed 38-40 h later. Couples were offered a maximum of three consecutive cycles. The primary outcome of the trial was live births. Secondary outcomes were pregnancy rates, multiple pregnancy rates, miscarriages and ovarian hyperstimulation syndrome rate. RESULTS: A total of 233 couples were included from January 2006 to February 2009, starting 572 treatment cycles. Live birth rates were not significantly different between the group treated with GnRH antagonist (8.4%; 23/275) and the placebo group (12%; 36/297) (P = 0.30). Three twin pregnancies occurred in the GnRH antagonist group and two twin pregnancies in the placebo group. CONCLUSIONS: Adding a GnRH antagonist in cycles with MOH in an IUI program does not increase live birth rates. Dutch Trial Register no: NTR497.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Gonadotropin-Releasing Hormone Ovarian Hyperstimulation Syndrome Adult Birth Rate Double-Blind Method Female Follicle Stimulating Hormone Follicle Stimulating Hormone Follicle Stimulating Hormone Gonadotropin-Releasing Hormone Humans Insemination, Artificial Ovarian Hyperstimulation Syndrome Ovulation Induction Ovulation Induction Pregnancy Pregnancy Rate

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

Cited by (2)

References (24)

Cited by (2)

Source provenance

europepmc
last seen: 2026-06-16T06:07:01.518242+00:00
openalex
last seen: 2026-05-11T06:27:45.971503+00:00
pubmed
last seen: 2026-05-13T22:16:48.482574+00:00
License: CC0 · commercial use OK